J&J's Risperdal "Not Approvable" In Alzheimer's Psychosis
This article was originally published in The Pink Sheet Daily
Executive Summary
The company issues its second announcement in a week that Risperdal has been deemed not approvable for a supplemental indication; FDA also issued a not approvable letter for risperidone for the treatment of autism.